Table 3.

Acute symptoms observed in the post-intervention period.

	Placebo (n = 48)	LF (n = 53)	RD (95% CI)	p
GASTROINTESTINAL SYMPTOM
Prevalence, n (%)	4 (8.3)	3 (5.7)	0.027 (−0.073, 0.127)	0.706
Total days	0 (0, 0)	0 (0, 0)		0.583
Duration, days/episode	1 (1, 1.75)	1 (1, 1)		0.386
Medication, n (%)	0 (0)	1 (33.3)		0.429
RESPIRATORY SYMPTOM
Prevalence, n (%)	25 (52.1)	16 (30.2)	0.219 (0.031, 0.407)	0.028
Total days	1 (0, 6)	0 (0, 1.5)		0.010
Duration, days/episode	5 (2, 8)	2 (1.25, 4.75)		0.177
Medication, n (%)	9 (36.0)	9 (56.3)		0.334

RD, risk difference; CI, confidence interval.

Values represent the number (%) or the median (interquartile range).

Prevalence is defined as the number of participants who experienced more than one symptom.

Total days are defined as the cumulative number of symptomatic days.

Duration is defined as the mean of consecutive days per episode.

Risk difference is calculated by subtracting the prevalence in the LF group from the prevalence in the placebo group.